Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Cardiovascular Medicine > Atrial Fibrillation > Flashcards

Atrial Fibrillation Flashcards

1
Q

Which of the following is not a common complication of atrial fibrillation?

A	Acute ischaemic stroke
B	Cardiac failure
C	Pulmonary embolism
D	Acute mesenteric ischaemia
E	Acute limb ischaemia
A

Pulmonary embolism may be a cause of, but not commonly a direct consequence of, atrial fibrillation.
Patients with atrial fibrillation are at risk of developing blood clots within the left atrial appendage. Stasis of blood promotes thrombus formation.

Embolisation to the brain may cause cerebral ischaemia. Embolisation to the limbs may cause acute limb ischaemia and to the bowel will cause acute mesenteric ischaemia. Patients with atrial fibrillation are also at risk of developing cardiac failure. There is a temporal relationship between atrial fibrillation and cardiac failure related to a number of shared risk factors and neurohormonal dysregulation that occurs in both conditions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

A 79-year-old female presents to the acute medical unit with a one-year history of dizzy spells. She does not complain of palpitations or chest pain but does get increasingly breathless on minimal exertion. She has a past medical history of hypertension and her only medication is ramipril. On examination, she has an irregular pulse at 130 bpm. An ECG is performed, which reveals an irregularly irregular rhythm and an absence of P waves. Her CHA2DS2-VASc score is 3.

What is the most appropriate initial treatment option from the choices below?

A    Apixaban and bisoprolol
B	Elective DC cardioversion
C	Heparin and amiodarone
D	Dabigatran monotherapy
E	Flecainide monotherapy
A

In patients with persistent AF the recommended management is rate control drugs (e.g. beta-blockers, calcium channel blockers) and anti-coagulation according to risk stratification.

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Older anti-coagulants (e.g. warfarin) are widely used for the prevention of thromboembolism in AF. However, patients should ideally be converted to DOACs - WHY?

A

Older anti-coagulants (e.g. warfarin) are widely used for the prevention of thromboembolism in AF. However, patients should ideally be converted to DOACs (e.g. apixaban) as they are better tolerated and do not require any monitoring. In the presence of new-onset AF, a DOAC should be offered first-line if advocated by a high CHADS-VASc score. If DOACs are not tolerated or not suitable, a vitamin K antagonist can be given.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

In the presence of new-onset AF, a … should be offered first-line if advocated by a high CHADS-VASc score.

A

In the presence of new-onset AF, a DOAC should be offered first-line if advocated by a high CHADS-VASc score.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

The … score is a risk stratification tool used in atrial fibrillation to determine those at greatest risk of cerebrovascular events.

A

The CHA2DS2-VASc score is a risk stratification tool used in atrial fibrillation to determine those at greatest risk of cerebrovascular events.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

NICE NG196 recommends anticoagulation (DOAC) in all patients with a score ≥ … taking into account bleeding risk. Anticoagulation should be considered in men with a score of 1. In women with a score of 1 due to gender, NICE does not consider this an indication for treatment.

A

NICE NG196 recommends anticoagulation (DOAC) in all patients with a score ≥ 2 taking into account bleeding risk. Anticoagulation should be considered in men with a score of 1. In women with a score of 1 due to gender, NICE does not consider this an indication for treatment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

A variety of non-cardiac causes may precipitate atrial fibrillation.

A

Respiratory: COPD, pneumonia, pulmonary emoblism
Endocrine: hyperthyroidism, diabetes mellitus
Acute infection
Electrolyte disturbances: hypokalaemia, hypomagnesaemia, hyponatraemia
Drugs: bronchodilators, thyroxine
Lifestyle factors: alcohol, excessive caffeine, obesity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Traditionally, causes of AF are divided into cardiac and non-cardiac. It is most commonly associated with hypertension, coronary artery disease and myocardial infarction.
Cardiac causes?

A 
Hypertension
Ischaemic heart disease
Valvular disease (e.g. rheumatic heart disease)
Myocardial infarction
Cardiomyopathy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

One of the major complications of AF is..

A

One of the major complications of AF is the formation of a thrombus (i.e. blood clot) within the atria.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Symptoms AF

A 
Asymptomatic
Palpitations
Shortness of breath
Angina
Presyncope
Lethargy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

AF signs

A

Irregularly irregular pulse
Absent ‘a’ wave on JVP: corresponds to atrial contraction
Tachycardia
Hypotension
Features of heart failure: bibasal crackles, raised JVP, peripheral oedem

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Causes of an irregularly irregular pulse include:

A

Atrial fibrillation
Premature beats (i.e. ectopics)
Atrial flutter with variable block
Other atrial tachyarrhythmias (e.g. multi-focal atrial tachycardia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

If AF is suspected, a formal diagnosis is made by performing a 12-lead ECG. Alternatively, if paroxysmal AF is suspected then ambulatory ECG monitoring can be requested:

A

24-hour monitoring: for asymptomatic episodes or symptomatic episodes < 24 hours apart
48-hour monitoring (occasionally completed)
7-day monitoring: longer period of monitoring if symptomatic episodes are infrequent
Loop recorder: a small device placed surgically under the skin. Provides continuous monitoring up to 3 years.
New technology: new software is available on smartwatches and phones that monitor for AF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Atrial fibrillation is characterised by …

A

Atrial fibrillation is characterised by an irregularly irregular rhythm, absent P waves and fibrillating baseline.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Both transthoracic echocardiography (TTE) and transoesophageal echocardiography (TOE) and important in the work-up and management of AF:

A

TTE: basic echo that involves imaging of the heart via the chest wall with an ultrasound probe
TOE: invasive echo that involves the insertion of an endoscope into the oesophagus to look at the heart with an ultrasound internally

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

TTE

A

A TTE is commonly requested routinely in patients with new-onset AF. This is because it helps with the long-term management of AF, particularly when a rhythm control strategy is opted for (discussed further below). It is also needed in patients where there is high risk of suspicion of an underlying structural heart defect (e.g. valvular heart disease or left ventricular dysfunction) or to refine risk stratification for the use of anticoagulation.

17
Q

TOE

A

A TOE is a more specialised imaging investigation that is typically used to better clarify structural abnormalities (e.g. valvular heart disease). It is also used to exclude a thrombus within the left atrial appendage (LAA) prior to cardioversion. This is because during cardioversion there is a risk of causing an embolic event and TOE is much better at visualising the LAA.

18
Q

Management of AF comprises a combination of …

A

Management of AF comprises a combination of rate control, rhythm control and prevention of thromboembolic events.

19
Q

NICE released new guidelines (NG196) for the diagnosis and management of AF in 2021 (NG196). This summarises the key components of management including:

A

Rate control
Rhythm control
Management of acute AF
Prevention of thromboembolic events

20
Q

In any new-onset AF, the underlying causes should be identified and treated (e.g. antibiotics for infection, antiplatelets for myocardial infarction). A decision then needs to be made as to whether patients should be treated with a rate or rhythm control strategy. Finally, patients need to be risk-stratified to decide on whether anticoagulation to reduce the risk of embolic events (e.g. stroke) is appropriate.

A

In any new-onset AF, the underlying causes should be identified and treated (e.g. antibiotics for infection, antiplatelets for myocardial infarction). A decision then needs to be made as to whether patients should be treated with a rate or rhythm control strategy. Finally, patients need to be risk-stratified to decide on whether anticoagulation to reduce the risk of embolic events (e.g. stroke) is appropriate.

21
Q

This is the most common type of management and aims to control AF that presents with a fast ventricular rate. In patients with AF that is not of acute onset, rate control is usually the first-line strategy.

Options include:

A

Beta-blockers (e.g. metoprolol, bisoprolol)
Rate-limiting calcium channel blockers (e.g. verapamil, diltiazem)
Digoxin: usually reserved for patients that do no or very little physical exercise (e.g. bedbound) or other drugs are inappropriate (contraindicated, side-effects, patient preference).

22
Q

Rhythm control aims to restore and/or maintain the heart in normal sinus rhythm. Rhythm control may either be pharmacological or electrical:

A

Pharmacological: using medications to restore and/or maintain sinus rhythm. Examples include amiodarone, flecainide, beta-blockers (e.g. sotalol).
Electrical: using DC cardioversion to revert the heart into sinus rhythm.

23
Q

Outside of acute onset AF, a rhythm control strategy is indicated in patients with ongoing symptomatic AF despite adequate rate control to improve quality of life. Patients who may be suitable for rhythm control include:

A

New-onset AF
Identifiable reversible cause
Heart failure (exacerbated by AF)
Associated with atrial flutter (and ablation strategy appropriate)
Rhythm control felt more suitable (clinical judgement)

24
Q

In patients presenting acutely with AF, it is first important to perform a clinical assessment (e.g. ABCDE) and determine haemodynamic stability:

A

Life-threatening haemodynamic instability: carry out emergency electrical cardioversion
Haemodynamic stability: rate or rhythm control strategies

25
Q

In patients who are stable, the key determinant to further management is the precise time of onset. This is because cardioversion (restoration of sinus rhythm) is associated with an increased risk of embolic events.

A

Onset > 48 hours or unclear: increased risk of thromboembolism. Patients need adequate anticoagulation (minimum 3 weeks) to reduce thromboembolic risk prior to cardioversion.
Onset < 48 hours: low risk of thromboembolism. Patients’ can be considered for immediate electrical or pharmacological cardioversion.

26
Q

In patients with early cardioversion (performed within 48 hours), pharmacological cardioversion is usually preferred with amiodarone or …. Assessment of the cardiac function with echocardiography is required because flecainide (type I antiarrhythmic) is dangerous in structural heart disease (pro-arrhythmic and increased risk of sudden cardiac death). Electrical cardioversion is usually preferred in delayed cardioversion.

A

In patients with early cardioversion (performed within 48 hours), pharmacological cardioversion is usually preferred with amiodarone or flecainide. Assessment of the cardiac function with echocardiography is required because flecainide (type I antiarrhythmic) is dangerous in structural heart disease (pro-arrhythmic and increased risk of sudden cardiac death). Electrical cardioversion is usually preferred in delayed cardioversion.

27
Q

Following cardioversion, anticoagulation is commonly given for a minimum of … weeks, even in patients at low-risk because of the risk of thromboembolism from atrial stunning post-restoration of sinus rhythm. Long-term continuation is then guided by usual risk stratification (i.e. CHADS-VASc).

A

Following cardioversion, anticoagulation is commonly given for a minimum of 4 weeks, even in patients at low-risk because of the risk of thromboembolism from atrial stunning post-restoration of sinus rhythm. Long-term continuation is then guided by usual risk stratification (i.e. CHADS-VASc).

28
Q

The two main options for anticoagulation include:

A

Vitamin K antagonists (e.g. warfarin): have been the mainstay for many years. Regular INR measurements are required. Target INR is usually 2-3.
Direct-acting oral anticoagulants (DOACs): newer agents such as Direct Xa inhibitors (e.g. apixaban, rivaroxaban) and direct thrombin inhibitors (e.g. Dabigatran). No monitoring is required.

29
Q

The CHA2DS2-VASc score is a risk stratification tool to assess stroke risk in patients with AF.

A

All patients with new-onset AF should have a CHA2DS2-VASc score calculated, which is a risk stratification tool to determine the annual risk of developing an embolic event. The result of this score can be used to guide the need for anticoagulation. DOACs should be offered first-line with warfarin used if a DOAC is not suitable or not tolerated.

NICE NG196 recommends anticoagulation (DOAC) in all patients with a score ≥ 2 taking into account bleeding risk. Anticoagulation should be considered in men with a score of 1. In women with a score of 1 due to gender, NICE do not consider this an indication for treatment. If a DOAC is not suitable or not tolerated, patients should be offered a vitamin K antagonist (e.g. warfarin).

30
Q

Patients with AF should undergo a formal risk assessment for major bleeding with anticoagulation using the ORBIT score.

A

In patients with AF who are being considered for anticoagulation based on the CHA2DS2-VASc score, an ORBIT score should be calculated.

OBRIT is a risk stratification tool to identified patients at risk of major bleeding events on anticoagulation. There are five total demains with a score from 0-7:
Haemoglobin (< 130 g/L males or < 120 g/L females): +2
Age > 74 years: +1
Bleeding history (GI bleeding, intracranial bleeding, haemorrhagic stroke): +2
eGFR < 60 mL/min/1.73 m2: +1
Treatment with antiplatelet: +1

31
Q

In patients with AF who are being considered for anticoagulation based on the CHA2DS2-VASc score, an ORBIT score should be calculated.

OBRIT is a risk stratification tool to identified patients at risk of major bleeding events on anticoagulation. There are five total demains with a score from 0-7:

A

Haemoglobin (< 130 g/L males or < 120 g/L females): +2
Age > 74 years: +1
Bleeding history (GI bleeding, intracranial bleeding, haemorrhagic stroke): +2
eGFR < 60 mL/min/1.73 m2: +1
Treatment with antiplatelet: +1

32
Q

HAS-BLED is an old risk stratification tool that was commonly used for the assessment of bleeding risk. NICE now recommends ORBIT as it has a higher accuracy of predicting bleeding risk. However, due to the widespread use of HAS-BLED, it may still be used until ORBIT is more formally embedded in clinical pathways and electronic systems.

A

HAS-BLED is an old risk stratification tool that was commonly used for the assessment of bleeding risk. NICE now recommends ORBIT as it has a higher accuracy of predicting bleeding risk. However, due to the widespread use of HAS-BLED, it may still be used until ORBIT is more formally embedded in clinical pathways and electronic systems.

33
Q

Catheter ablation

A

AF catheter ablation is an alternative treatment to long-term anti-arrhythmic drugs to maintain sinus rhythm that involves modification of the left atrium through ablation.

34
Q

Patients with infrequent paroxysmal AF may be treated with a ‘…’ regimen

A

Patients with infrequent paroxysmal AF may be treated with a ‘pill-in-pocket’ regimen.

35
Q

Patients with infrequent episodes of paroxysmal AF may not require long-term antiarrhythmic therapy. In selected outpatients, self-administration of .. at the onset of AF to induce pharmacological cardioversion may be preferred to in-hospital pharmacological cardioversion. The drug should be safe to use, previously shown efficacy and there be no evidence of structural or ischaemic heart disease. … may be combined with a beta-blocker in this type of patient-led cardioversion.

A

Patients with infrequent episodes of paroxysmal AF may not require long-term antiarrhythmic therapy. In selected outpatients, self-administration of flecainide at the onset of AF to induce pharmacological cardioversion may be preferred to in-hospital pharmacological cardioversion. The drug should be safe to use, previously shown efficacy and there be no evidence of structural or ischaemic heart disease. Flecainide may be combined with a beta-blocker in this type of patient-led cardioversion.

36
Q

AF is associated with both cardiac and non-cardiac complications.

A

Cardiac

Heart failure
Tachycardia-induced cardiomyopathy
Ischaemia
Sudden cardiac arrest
Non-cardiac

Thromboembolic events: stroke, TIA, mesenteric ischaemia, ischaemic limb
Collapse
Bleeding events (anticoagulation)

Cardiovascular Medicine (28 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions